Androgen deprivation therapy complications

Endocrine-Related Cancer

Volumn 21, Issue 4, 2014, Pages

  Allan, Carolyn A ^a,b,c   Collins, Veronica R ^b   Frydenberg, Mark ^b,c   McLachlan, Robert I ^a,b,c   Matthiesson, Kati L ^a,c  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c SOUTHERN HEALTH   (Australia)

Author keywords

Androgen deprivation therapy; Bone; Cardiovascular disease; Diabetes; Fracture; Osteoporosis; Prostate cancer; Quality of life

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TESTOSTERONE; TRIACYLGLYCEROL;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANEMIA; BODY COMPOSITION; BODY WEIGHT DISORDER; BONE DENSITY; CANCER ADJUVANT THERAPY; CARDIOMETABOLIC RISK; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COGNITION; COGNITIVE DEFECT; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT MASS; FATIGUE; FRAGILITY FRACTURE; GYNECOMASTIA; HIP FRACTURE; HOT FLUSH; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEAN BODY WEIGHT; MALE; MALE SEXUAL DYSFUNCTION; MOOD; MOOD DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOLYSIS; OSTEOPOROSIS; PROSTATE CANCER; PSYCHOSEXUAL DISORDER; QUALITY OF LIFE; REVIEW; SPINE FRACTURE; AFFECT; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DRUG EFFECTS; PROSTATIC NEOPLASMS; SEXUAL DYSFUNCTION;

AFFECT; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; BONE RESORPTION; CARDIOVASCULAR DISEASES; COGNITION; HOT FLASHES; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 84905963112     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0467     Document Type: Review

References (89)

1. Abrahamsson PA 2010 Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. European Urology 57 49-59. (doi:10.1016/j.eururo.2009.07.049)
2. Ahmadi H & Daneshmand S 2013 Androgen deprivation therapy: evidence-based management of side effects, BJU International 111 543-548. (doi:10.1111/j.1464-410X.2012.11774.x)
3. Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM & Paszat LF 2009 Impact of androgen deprivation therapy on cardiovascular disease and diabetes. Journal of Clinical Oncology 27 3452-3458. (doi:10.1200/JCO.2008.20.0923)
4. Alibhai SM, Breunis H, Timilshina N, Marzouk S, Stewart D, Tannock I, Naglie G, Tomlinson G, Fleshner N, Krahn M et al. 2010a Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. Journal of Clinical Oncology 28 5030-5037. (doi:10.1200/JCO. 2010.30.8742)
5. Alibhai SM, Breunis H, Timilshina N, Johnston C, Tomlinson G, Tannock I, Krahn M, Fleshner NE, Warde P, Canning SD et al. 2010b Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. Journal of Clinical Oncology 28 5038-5045. (doi:10.1200/JCO.2010.29.8091)
6. Allan CA, Collins VR, Frydenberg M, McLachlan RI & Matthiesson KL 2012 Monitoring cardiovascular health in men with prostate cancer treated with androgen deprivation therapy. International Journal of Urological Nursing 6 35-41. (doi:10.1111/j.1749-771X.2011.01135.x)
7. van Andel G, Bottomley A, Fossa SD, Efficace F, Coens C, Guerif S, Kynaston H, Gontero P, Thalmann G, Akdas A et al. 2008 An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. European Journal of Cancer 44 2418-2424. (doi:10.1016/j.ejca.2008.07.030)
8. Ashamalla H, Jiang ML, Guirguis A, Peluso F & Ashamalla M 2011 Acupuncture for the alleviation of hot flashes in men treated with androgen ablation therapy. International Journal of Radiation Oncology, Biology, Physics 79 1358-1363. (doi:10.1016/j.ijrobp.2010.01.025)
9. Aversa A, Isidori AM, De Martino MU, Caprio M, Fabbrini E, Rocchietti- March M, Frajese G & Fabbri A 2000 Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clinical Endocrinology 53 517-522. (doi:10.1046/j.1365-2265.2000.01118.x)
10. Azoulay L, Yin H, Benayoun S, Renoux C, Boivin JF & Suissa S 2011 Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. European Urology 60 1244-1250. (doi:10.1016/j.eururo.2011.08.041)
11. Basaria S 2008 Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. Journal of Andrology 29 534-539. (doi:10.2164/jandrol.108.005454)
12. Basaria S, Lieb J II, Tang AM, DeWeese T, Carducci M, Eisenberger M & Dobs AS 2002 Long-term effects of androgen deprivation therapy in prostate cancer patients. Clinical Endocrinology 56 779-786. (doi:10.1046/j.1365-2265. 2002.01551.x)
13. Basaria S, Muller DC, Carducci MA, Egan J & Dobs AS 2006 Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106 581-588. (doi:10.1002/cncr.21642)
14. Beer TM, Benavides M, Emmons SL, Hayes M, Liu G, Garzotto M, Donovan D, Katovic N, Reeder C & Eilers K 2010 Acupuncture for hot flashes in patients with prostate cancer. Urology 76 1182-1188. (doi:10.1016/j.urology.2010.03.033)
15. Boxer RS, Kenny AM, Dowsett R & Taxel P 2005 The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer. Aging Male 8 207-212. (doi:10.1080/13685530500361226)
16. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J & Basaria S 2006 Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. Journal of Clinical Oncology 24 3979-3983. (doi:10.1200/JCO.2006.05.9741)
17. Charig CR & Rundle JS 1989 Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma. Urology 33 175-178. (doi:10.1016/0090-4295(89)90385-3)
18. Cherrier MM, Aubin S & Higano CS 2009 Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. Psycho-Oncology 18 237-247. (doi:10.1002/pon.1401)
19. Chung SD, Chen YK, Wu FJ & Lin HC 2012 Hormone therapy for prostate cancer and the risk of stroke: a 5-year follow-up study. BJU International 109 1001-1005. (doi:10.1111/j.1464-410X.2011.10459.x)
20. D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C et al. 2007 Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. Journal of Clinical Oncology 25 2420-2425. (doi:10.1200/JCO.2006. 09.3369)
21. Derweesh IH, Diblasio CJ, Kincade MC, Malcolm JB, Lamar KD, Patterson AL, Kitabchi AE & Wake RW 2007 Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU International 100 1060-1065. (Pubitemid 47537673)
22. Diamond TH, Winters J, Smith A, De Souza P, Kersley JH, Lynch WJ & Bryant C 2001 The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 92 1444-1450. (doi:10.1002/1097-0142(20010915)92:6 〈1444::AID-CNCR1468 O3.0.CO;2-M〉
23. Diamond TH, Bucci J, Kersley JH, Aslan P, Lynch WB & Bryant C 2004 Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy. Journal of Urology 172 529-532. (doi:10.1097/01.ju.0000130508.61020.66)
24. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M & Rajkumar C 2003 Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clinical Science 104 195-201. (doi:10.1042/CS20020209)
25. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM & Smith MR 2009 Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. Journal of Clinical Oncology 27 92-99. (doi:10.1200/JCO.2007.12.3752)
26. Engel J, Bastian PJ, Baur H, Beer V, Chaussy C, Gschwend JE, Oberneder R, Rothenberger KH, Stief CG & Holzel D 2010 Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. European Urology 57 754-761. (doi:10.1016/j.eururo.2009.12.034)
27. Greenspan SL 2008 Approach to the prostate cancer patient with bone disease. Journal of Clinical Endocrinology and Metabolism 93 2-7. (doi:10.1210/jc.2007-1402)
28. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL & Resnick NM 2005 Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. Journal of Clinical Endocrinology and Metabolism 90 6410-6417. (doi:10.1210/jc.2005-0183)
29. Greenspan SL, Nelson JB, Trump DL & Resnick NM 2007 Effect of onceweekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Annals of Internal Medicine 146 416-424. (doi:10.7326/0003-4819-146-6-200703200-00006)
30. Greenspan SL, Nelson JB, Trump DL, Wagner JM, Miller ME, Perera S & Resnick NM 2008 Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. Journal of Clinical Oncology 26 4426-4434. (doi:10.1200/JCO.2007.15.1233)
31. Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL & Zajac JD 2011 Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Medical Journal of Australia 194 301-306.
32. Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D, Bolton D, Zajac JD & Grossmann M 2011 Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clinical Endocrinology 74 377-383. (doi:10.1111/j.1365-2265.2010.03942.x)
33. Haseen F, Murray LJ, Cardwell CR, O'Sullivan JM & Cantwell MM 2010 The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. Journal of Cancer Survivorship 4 128-139. (doi:10.1007/s11764-009-0114-1)
34. Holmes-Walker DJ, Woo H, Gurney H, Do VT & Chipps DR 2006 Maintaining bone health in patients with prostate cancer. Medical Journal of Australia 184 176-179.
35. Hussain SA, Weston R, Stephenson RN, George E & Parr NJ 2003 Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU International 92 690-694. (doi:10.1046/j.1464-410X.2003.04471. x)
36. Irani J, Salomon L, Oba R, Bouchard P & Mottet N 2010 Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropinreleasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncology 11 147-154. (doi:10.1016/S1470-2045(09)70338-9)
37. Jamadar RJ, Winters MJ & Maki PM 2012 Cognitive changes associated with ADT: a review of the literature. Asian Journal of Andrology 14 232-238. (doi:10.1038/aja.2011.107)
38. Joly F, Alibhai SM, Galica J, Park A, Yi QL, Wagner L & Tannock IF 2006 Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. Journal of Urology 176 2443-2447. (doi:10.1016/j.juro.2006.07.151)
39. Karling P, Hammar M & Varenhorst E 1994 Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. Journal of Urology 152 1170-1173. (Pubitemid 24283460)
40. Keating NL, O'Malley AJ & Smith MR 2006 Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology 24 4448-4456. (doi:10.1200/JCO.2006.06.2497)
41. Keating NL, O'Malley AJ, Freedland SJ & Smith MR 2010 Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. Journal of the National Cancer Institute 102 39-46. (doi:10.1093/jnci/djp404)
42. Keating NL, O'Malley AJ, Freedland SJ & Smith MR 2013 Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? European Urology 64 159-166. (doi:10.1016/j.eururo.2012.04.035)
43. Ketchandji M, Kuo YF, Shahinian VB & Goodwin JS 2009 Cause of death in older men after the diagnosis of prostate cancer. Journal of the American Geriatrics Society 57 24-30. (doi:10.1111/j.1532-5415.2008.02091.x)
44. Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL, Carson C III, Cheitlin M, Debusk R, Fonseca V et al. 2005 Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). American Journal of Cardiology 96 85M-93M. (doi:10.1016/j.amjcard.2005.12.018)
45. Lattouf JB, Fadlallah H & Saad F 2011 Androgen deprivation and bone. Current Osteoporosis Reports 9 20-24. (doi:10.1007/s11914-010-0045-9)
46. Lee H, McGovern K, Finkelstein JS & Smith MR 2005 Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 104 1633-1637. (doi:10.1002/cncr.21381)
47. Lee CE, Leslie WD, Czaykowski P, Gingerich J, Geirnaert M & Lau YK 2011 A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy. Current Oncology 18 e163-e172. (doi:10.3747/co.v18i4.746)
48. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N et al. 2010 Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 121 833-840. (doi:10.1161/CIRCULATIONAHA.109.192695)
49. van Londen GJ, Levy ME, Perera S, Nelson JB & Greenspan SL 2008 Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study. Critical Reviews in Oncology/Hematology 68 172-177. (doi:10.1016/j.critrevonc.2008.06.006)
50. Loprinzi CL, Goldberg RM, O'Fallon JR, Quella SK, Miser AW, Mynderse LA, Brown LD, Tschetter LK, Wilwerding MB, Dose M et al. 1994 Transdermal clonidine for ameliorating post-orchiectomy hot flashes. Journal of Urology 151 634-636. (Pubitemid 24054699)
51. Loprinzi CL, Dueck AC, Khoyratty BS, Barton DL, Jafar S, Rowland KM Jr, Atherton PJ, Marsa GW, Knutson WH, Bearden JD III et al. 2009 A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Annals of Oncology 20 542-549. (doi:10.1093/annonc/mdn644)
52. Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS & Smith MR 2007 Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonistinduced bone loss in men with prostate cancer. Journal of Clinical Oncology 25 1038-1042. (doi:10.1200/JCO.2006.07.3361)
53. Nanda A, Chen MH, Braccioforte MH, Moran BJ & D'Amico AV 2009 Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. Journal of the American Medical Association 302 866-873. (doi:10.1001/jama.2009. 1137)
54. Nelson CJ, Lee JS, Gamboa MC & Roth AJ 2008 Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer 113 1097-1106. (doi:10.1002/cncr.23658)
55. Neubecker K, Adams-Huet B, Farukhi IM, Delapena RC & Gruntmanis U 2011 Predictors of fracture risk and bone mineral density in men with prostate cancer on androgen deprivation therapy. Journal of Osteoporosis 2011 924595. (doi:10.4061/2011/924595)
56. Newton RU, Taaffe DR, Spry N, Cormie P, Chambers SK, Gardiner RA, Shum DH, Joseph D & Galvao DA 2012 Can exercise ameliorate treatment toxicity during the initial phase of testosterone deprivation in prostate cancer patients? Is this more effective than delayed rehabilitation? BMC Cancer 12 432. (doi:10.1186/1471-2407-12-432)
57. Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA & Choueiri TK 2011 Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. Journal of the American Medical Association 306 2359-2366.
58. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, Albus C, Benlian P, Boysen G, Cifkova R et al. 2012 European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). International Journal of Behavioral Medicine 19 403-488. (doi:10.1007/s12529-012-9242-5)
59. Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, Albertsen PC, Gilliland FD & Stanford JL 2002 Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. Journal of the National Cancer Institute 94 430-437. (doi:10.1093/jnci/94.6.430)
60. Quella SK, Loprinzi CL, Sloan J, Novotny P, Perez EA, Burch PA, Antolak SJ Jr & Pisansky TM 1999 Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. Journal of Urology 162 98-102. (doi:10.1097/00005392-199907000-00024)
61. Roach M III, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D & Pilepich MV 2008 Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. Journal of Clinical Oncology 26 585-591. (doi:10.1200/JCO.2007.13.9881)
62. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS & Urologic Diseases in America Project 2007 Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110 1493-1500. (doi:10.1002/cncr.22933)
63. Salvador C, Planas J, Agreda F, Placer J, Trilla E, Lopez MA & Morote J 2013 Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients. Urologia Internationalis 90 41-44. (doi:10.1159/000342814)
64. Sarosdy MF, Schellhammer PF, Soloway MS, Vogelzang NJ, Crawford ED, Presti J, Chodak GW, Mitchell P & Porter L 1999 Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU International 83 801-806. (doi:10.1046/j.1464-410x.1999.00028.x)
65. Saylor PJ, Keating NL & Smith MR 2009 Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. Journal of General Internal Medicine 24 (Suppl 2) S389-S394. (doi:10.1007/s11606-009-0968-y)
66. Schow DA, Renfer LG, Rozanski TA & Thompson IM 1998 Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. Southern Medical Journal 91 855-857. (doi:10.1097/00007611-199809000- 00010)
67. Serpa Neto A, Tobias-Machado M, Esteves MA, Senra MD, Wroclawski ML, Fonseca FL, Dos Reis RB, Pompeo AC & Giglio AD 2012 Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases 15 36-44. (doi:10.1038/pcan.2011.4)
68. Shahani S, Braga-Basaria M & Basaria S 2008 Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. Journal of Clinical Endocrinology and Metabolism 93 2042-2049. (doi:10.1210/jc.2007-2595)
69. Shahinian VB, Kuo YF, Freeman JL & Goodwin JS 2005 Risk of fracture after androgen deprivation for prostate cancer. New England Journal of Medicine 352 154-164. (doi:10.1056/NEJMoa041943)
70. Shahinian VB, Kuo YF, Freeman JL & Goodwin JS 2006 Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Archives of Internal Medicine 166 465-471.
71. Smith MR 2004 Changes in fat and lean body mass during androgendeprivation therapy for prostate cancer. Urology 63 742-745. (doi:10.1016/j.urology.2003.10.063)
72. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW & Finkelstein JS 2001 a Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. New England Journal of Medicine 345 948-955. (doi:10.1056/NEJMoa010845)
73. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, Cockcroft JR, Scanlon MF & Davies JS 2001b The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. Journal of Clinical Endocrinology and Metabolism 86 4261-4267. (doi:10.1210/jcem.86.9.7851)
74. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA & Kantoff PW2002 Changes in body composition during androgen deprivation therapy for prostate cancer. Journal of Clinical Endocrinology and Metabolism 87 599-603. (doi:10.1210/jcem.87.2.8299)
75. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S & Zinner N 2003 Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. Journal of Urology 169 2008-2012. (doi:10.1097/01.ju.0000063820.94994.95)
76. Smith MR, Fallon MA, Lee H & Finkelstein JS 2004 Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 89 3841-3846. (doi:10.1210/jc.2003-032058)
77. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK & Brandman J 2006a Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. Journal of Urology 175 136-139 (discussion 139). (doi:10.1016/S0022-5347(05)00033-9)
78. Smith MR, Lee H & Nathan DM 2006b Insulin sensitivity during combined androgen blockade for prostate cancer. Journal of Clinical Endocrinology and Metabolism 91 1305-1308. (doi:10.1210/jc.2005-2507)
79. Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A et al. 2009 Denosumab in men receiving androgen-deprivation therapy for prostate cancer. New England Journal of Medicine 361 745-755. (doi:10.1056/NEJMoa0809003)
80. Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML & Steiner MS 2013 Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. Journal of Urology 189 S45-S50. (doi:10.1016/j.juro.2012.11.016)
81. Sonn GA, Sadetsky N, Presti JC & Litwin MS 2013 Differing perceptions of quality of life in patients with prostate cancer and their doctors. Journal of Urology 189 S59-S65 (discussion S65). (doi:10.1016/j.juro.2012.11.032)
82. Storer TW, Miciek R & Travison TG 2012 Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. Asian Journal of Andrology 14 204-221. (doi:10.1038/aja.2011.104)
83. Studer UE, Collette L, Whelan P, Albrecht W, Casselman J, de Reijke T, Knonagel H, Loidl W, Isorna S, Sundaram SK et al. 2008 Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). European Urology 53 941-949. (doi:10.1016/j.eururo.2007.12.032)
84. Traish AM & Guay AT 2006 Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence Journal of Sexual Medicine 3 382-404 (discussion 404-407). (doi:10.1111/j.1743-6109.2006.00245.x)
85. Tsai HK, D'Amico AV, Sadetsky N, Chen MH & Carroll PR 2007 Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Journal of the National Cancer Institute 99 1516-1524. (doi:10.1093/jnci/djm168)
86. Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, Akl EA, Lansberg MG, Guyatt GH, Spencer FA et al. 2012 Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 e637S-e668S. (doi:10.1378/chest.11-2306)
87. Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, Lambe M, Stattin P & Adolfsson J 2010 Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. Journal of Clinical Oncology 28 3448-3456. (doi:10.1200/JCO.2010.29.1567)
88. Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, Finkelstein JS & Endocrine S 2012 Osteoporosis in men: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 97 1802-1822. (doi:10.1210/jc.2011-3045)
89. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J, Vardi Y & EAU 2006 EAU Guidelines on erectile dysfunction: an update. European Urology 49 806-815. (doi:10.1016/j.eururo.2006.01.028)